REG1 [anivamersen-pegnivacogin] versus pegnivacogin alone in patients with stable coronary artery disease receiving aspirin +/- clopidogrel

Trial Profile

REG1 [anivamersen-pegnivacogin] versus pegnivacogin alone in patients with stable coronary artery disease receiving aspirin +/- clopidogrel

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2008

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Pegnivacogin
  • Indications Coronary artery disease; Venous thrombosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 03 Sep 2008 Results have been published in the proceedings of the ESC Congress 2008: Annual Congress of the European Society of Cardiology.
    • 12 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top